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Objectives: The present study aims to prospectively evaluate quality of life (QoL) 
of women using 52 mg levonorgestrel intrauterine system for contraception 
determined through the SEC-QoL, a questionnaire specifically designed to assess 
the impact of contraceptive methods on QoL of fertile women. 
Study design: We conducted a prospective observational multicenter study of 201 
reproductive age women who initiated the levonorgestrel intrauterine system (LNG-
IUS) for contraception. Sociodemographic and clinical data were collected at 
baseline and 12 months afterwards. Participants filled in the SEC-QoL questionnaire 
at both visits. SEQ-QoL scores range from 0 (worst QoL) to 100 (best QoL).   
Results: Participants claimed an increased QoL 12 months after insertion in all five 
dimensions of SEC-QoL due to its high contraceptive efficacy and its capability to 
reduce other menstrual symptoms (e.g. heavy menstrual bleeding or 
dysmenorrhoea), overall exerting a positive impact on user’s satisfaction. SEC-QoL 
general overall score went from a mean (SD) score of 46.3 (17.3) at baseline to 
72.2 (14.8) 12 months afterwards (p<0.001). Overall, 94.6% of women claimed 
having found additional benefits other than contraception. No pregnancies were 
reported during the 12 months of study duration and only 14 women discontinued 
use of LNG-IUS (only two of them due to an adverse event), representing a 
continuation rate of 93%. 
Conclusions: Women using LNG-IUS for contraception have an increased QoL after 




The present study prospectively evaluated QoL of women using LNG-IUS for 
contraception through the SEC-QoL questionnaire. Participants claimed increased 















in usual clinical practice also benefit from the reduction of period-related 
symptoms, overall leading to very low discontinuation rates.   
 
Key Words: Intrauterine System / Levonorgestrel / Quality of Life / Contraception 
/ SEQ-QoL questionnaire 
 
1. Introduction 
Levonorgestrel intrauterine system (LNG-IUS) exhibits a very low discontinuation 
rate and very good level of satisfaction within its users [1‒3]. Particularly, several 
studies reveal that benefits associated to LNG-IUS are not only related to its 
contraception efficacy [4], but are also due to its capability to reduce other 
menstrual and premenstrual symptoms [5,6] which exert a negative impact on 
women’s health related quality of life (HRQoL) [7‒10]. Given the benefit provided 
by LNG-IUS in the reduction of heavy menstrual bleeding (HMB), the National 
Institute for Health and Care Excellence (NICE) institute in the UK recommended it 
as first line treatment for HMB in 2007 [11], and the Food and Drug Administration 
(FDA) approved its use for this indication in 2009.  
 
Several studies have been conducted to assess HRQoL in women using LNG-IUS to 
reduce HBM [12,13]; as well as for women using it for contraception [14‒16], in 
which HRQoL was assessed through generic questionnaires (i.e. EQ-5D or SF-36) 
[17]. 
  
However, to the best of our knowledge, there is a lack of studies aiming to 
determine the level of satisfaction and HRQoL of women using LNG-IUS for 
contraception, particularly, those in which HRQoL was assessed through 
questionnaires specifically designed for fertile women under contraception like the 
















In this context, the present study aims to assess the impact of 52 mg LNG-IUS 
used for contraception on HRQoL of women, after 12 months of use through the 
SEC-QoL questionnaire in Spain. 
 
2. Material and methods 
2.1 Study design 
We conducted a prospective observational multicenter study of 201 reproductive 
age women who initiated the 52 mg LNG-IUS for contraception. The cohort included 
women aged from 18 to 49 who were recruited from 18 private gynaecological 
centres in Spain, after giving written informed consent. Women were eligible to 
participate in this study unless they (i) presented contraindications for LNG-IUS, (ii) 
were using LNG-IUS for non-contraceptive purposes such as HMB, (iii) had used 
any other kind of hormonal contraceptives 3 months prior to study inclusion, (iv) 
were unable to fill in the study questionnaire, (v) were participating in other clinical 
trials. The study was conducted following current Spanish regulations for post-
authorization studies, and was approved by the Spanish Agency of Medicine and 
Health Products and the Hospital la Zarzuela Research Ethic Committee.  
 
The present study consisted of two visits: when starting use of LNG-IUS (baseline) 
and 12 months afterwards (final visit). Sociodemographic and clinical data were 
collected from medical charts or from the interviews conducted during the study 
visits. At baseline (when LNG-IUS was introduced), the following sociodemographic 
data was collected: age, level of education, employment status and marital status. 
Both at baseline and final visits, the following clinical data was collected: bleeding 
intensity, painful menstrual periods (measured through a visual analogue scale 
(VAS) ranging from 0: “no pain” to 10: “maximum pain”), menstrual and 
premenstrual breast symptoms, and presence of non-contraception benefits from 
LNG-IUS (reduction of period-related symptoms, improvement of anaemia, 















others). Period-related symptoms were assessed on the basis of women’s personal 
perception. In order to determine HRQoL evolution of included women, they were 
asked to fill in, both at baseline (straight after introducing LNG-IUS) and at final 
visits, the self-administered SEC-QoL questionnaire [18]; a specific HRQoL 
questionnaire for fertile women on contraception which consists of 19 items 
distributed in five dimensions: “social” (5 items), “menstrual symptoms” (4 items), 
“breast symptoms” (3 items), “psychological” (4 items) and “sexual” (3 items); 
each item allowing for five liker-type response choices (from “always” to “never” or 
from “totally agree” to “totally disagree”, depending on the kind of statement). 
Overall scores were obtained by adding up the responses from the corresponding 
items, which were subsequently standardised to a scale ranging from 0 (worst 
HRQoL) to 100 (best HRQoL). In addition, at the final visit, women were asked 
about their general level of satisfaction with the method using a VAS graded from 0 
(“not satisfied at all”) to 10 (“very satisfied”).  
 
2.2 Sample size  
Sample size was calculated in order to detect changes in terms of HRQoL measured 
through the SEC-QoL questionnaire at baseline and final visits. According to the 
validation study of the SEC-QoL questionnaire, in which women initiating 
contraception went from a mean (SD) score of 46.6 (17.8) to 57.0 (18.4) [18], a 
minimal important difference (MID), the smallest change in score at baseline and 
final visits required to be considered clinically relevant, was established at 3.4 
points. However, the SEC-QoL validation study included women using many 
different contraceptive methods, whereas in the present study only women using 
LNG-IUS were included, thus a more conservative approach was considered for the 
sample size calculation. In this context, in order to detect changes ≥5 between 
scores reported at baseline and final visits, assuming a deviation of 18, a 
significance level of 0.05, a statistical power of 0.8 and at least 10% of dropouts, a 
















2.3 Statistical Analysis 
All women fulfilling inclusion criteria were included in the analysis, except those 
who had not completed the SEC-QoL questionnaire at baseline. Women who 
discontinued the study and reason for discontinuation were also collected. A 
descriptive analysis of sociodemographic and clinical data and scores from the SEC-
QoL questionnaire at baseline and final visits was conducted. Correlation between 
SEC-QoL results and sociodemographic and clinical variables was determined 
through the ANOVA test and Pearson correlation coefficient. The MID was 
established at 3.4 points for the overall score in the context of the validation of the 
SEC-QoL questionnaire [18]. Finally, impact of menstrual symptoms on HRQoL and 
the scores reported at each SEC-QoL dimension, was analysed through a lineal 
regression model. Statistical analysis was performed using the SAS system version 
9.2 (SAS Institute Inc., Cary, NC, USA) in Windows™ operating system support. A 
level of statistical significance (p) of 0.05 was established for all correlations.  
 
3. Results 
Out of the 201 included women, 14 did not complete the entire study: 7 dropouts, 
5 due to LNG-IUS discontinuation (2 due to an adverse event: bleeding between 
periods and abdominal discomfort; 2 because of device expulsion; and 1 due to 
willingness to become pregnant), 1 due to woman’s personal opinion and 1 because 
of death or serious disease not related to the medication. Table 1 summarises some 
of the most relevant sociodemographic data. Mean (SD) age of participants was 
38.7 (5.0). It is worth noting that more than 60% of included women had 
completed University education, 96.5% claimed having a stable partner at baseline, 
95% had had at least one baby and 40% had carried two pregnancies to term. 
Regarding contraception methods used the year before starting use of LNG-IUS, the 

















In order to fulfil the primary objective of the present study, the SEC-QoL score 
evolution was analysed. At baseline, mean (SD) overall score was 46.3 (17.3), 
which increased to 72.2 (14.8) 12 months afterwards; scores in all dimensions 
experiencing a statistically significant improvement (p<0.001). Figure 1 shows the 
scores reported in all dimensions at baseline and 12 months afterwards. Moreover, 
when comparing the mean overall score reported at both visits, 91.7% of women 
experienced a positive and statistically significant evolution in terms of HRQoL, 
which corresponded to the percentage of scores that reached the MID established 
for this questionnaire at the validation process [18]. In addition, women who, 
according to their personal perception, claimed suffering HMB at baseline, reported 
lower scores in all SEC-QoL dimensions (<0.05). Similarly, increased painful 
menstrual periods related to lower scores from all SEC-QoL questionnaire 
dimensions (p<0.005).  
 
Figure 1 also shows the p values for the correlation between changes in SEC-QoL 
scores between visits with changes in bleeding intensity and painful menstrual 
periods also between visits. As can be observed from figure 2, reduction of 
menstrual bleeding intensity did not exert a statistically significant effect on HRQoL 
(p>0.05 in all SEC-QoL dimensions), whereas reduction of painful menstrual 
periods did significantly correlate with an increased HRQoL (p≤0.007 in all 
dimensions of the SEC-QoL).    
 
Furthermore, during the 12 months of study duration, no pregnancies were 
reported and the overall level of satisfaction was 8.4. In addition, 94.6% of women 
claimed having found additional benefits associated to LNG-IUS other than 
contraception; participants reported having experienced a reduction of bleeding 
(90.9%), and menstrual (45.2%) and premenstrual (39.8%) symptoms. For 















claimed having had HMB three months prior to the study inclusion (when they 
started using LNG-IUS), whereas none of them reported suffering it 12 months 
afterwards; 96.8% reporting limited or very limited bleeding (p<0.001). 
Furthermore, a reduction in painful menstrual periods was also reported; on a 0 (no 
pain) to 10 (maximum pain) scale, the mean (SD) score going from 3.8 (2.7) at 
baseline to 0.9 (1.3) at the final visit. Also, 44.8% of women reported scores 
between 4 and 10 at baseline, whereas 12 months afterwards, 87.6% of women 
reported scores below 2 (no pain). The aforementioned positive results translated 
into a very high continuation rate (93%). 
 
4. Discussion 
The present study assesses HRQoL of women using LNG-IUS for contraception 
through the only validated questionnaire specifically designed for fertile women 
using contraceptives, thus providing novel information on the effect of LNG-IUS on 
its 5 specific dimensions (social, menstrual symptoms, breast symptoms, 
psychological and sexual) that could not be assessed in previous studies as they 
employed generic questionnaires (i.e. SF-36 or EQ-5D) [12‒17]. Thus, SEC-QoL 
has proved to be a unique and useful tool to assess changes in HRQoL in LNG-IUS 
users. Also, further reinforcing previously reported results [14‒16], our findings 
conclude that women using LNG-IUS for contraception have increased HRQoL 12 
months after insertion, which is reflected through an increased score in all five 
dimensions of the SEC-QoL questionnaire.  
 
Moreover, participants claimed a high overall level of satisfaction (8.4 on a 0 to 10 
scale); which again is consistent with previous studies, in which around 80% of 
women claimed being satisfied with LNG-IUS after a year of use [6,15]. However, 
caution should be taken when comparing level of satisfaction from different studies 
















Furthermore, participants claimed having experienced non-contraceptive benefits 
(i.e. reduction of bleeding, menstrual pain and general menstrual and pre-
menstrual symptoms), which clearly had an effect on HRQoL. These benefits are 
consistent with those reported in previous studies which claimed that LNG-IUS 
significantly reduced painful periods and menstrual bleeding [6,15,19,20]; and also 
that these benefits were more commonly reported in women using LNG-IUS than in 
those using hormonal contraceptives, even to combined oral contraceptive pill 
[21,22]. 
  
In addition, consistently with previous results reported in terms of effectiveness 
and safety of LNG-IUS as a contraceptive method [1‒3]; the lack of pregnancies 
being reported during the 12 months of study duration, together with the low 
discontinuation rate and the fact that only two women withdrew LNG-IUS due to an 
adverse event, further reinforce effectiveness and safety of LNG-IUS as a 
contraceptive method.  
 
In the context of the SEC-QoL validation study, HRQoL of women using different 
contraceptive methods was assessed, both using a generic (EQ-5D) and specific 
questionnaire (SEC-QoL); and in spite of it leading to conclude that the SEC-QoL 
was a valid tool for use in clinical practice, the study only included 6 women using 
IUS [18]. In order to validate the SEC-QoL, the authors defined three study groups 
according to the type of contraceptive method of choice (effective, poorly effective 
or none). Women choosing effective contraceptive methods (hormonal 
contraceptives, consistent use of barrier methods, intrauterine devices, implants 
and injectables, male or female sterilization and dual methods) reported 
significantly higher level of education; similarly, a highly percentage of women 
participating in the present study claimed having University education (62.8%). 
Also, the SEC-QoL validation study concluded that women using effective 















QoL (better HRQoL) compared to women using none or poorly effective methods. 
Mean SEC-QoL scores were lower than those reported at the final visit of the 
present study. 
 
Despite real-life studies being necessary to confirm results from controlled clinical 
trials, the lack of intense monitoring or a control group may restrict the validity of 
their findings, thus representing a study limitation. Also, unlike previous studies in 
which the level of menstrual bleeding was measured through specific tests [23], in 
the present study period-related symptoms were assessed through women personal 
perception which may difficult comparison of our findings with previous studies due 
to interpersonal perception variability.  
 
One of the main strengths of the present study is the methodology applied. A 
questionnaire specifically designed for fertile women using contraceptives has been 
used (SEC-QoL) which strengthens the validity of our findings. Also, two study 
visits have been included, when initiating use of LNG-IUS and 12 months 
afterwards, which has allowed the evaluation of HRQoL, satisfaction and menstrual 
symptoms evolution. However, another limitation of the present study is that 
HRQoL of women who discontinued the study was not assessed as they did not 
attend the final visit, thus, albeit small, the potential reduction of SEC-QoL mean 
score due to adverse events (n=2) or LNG-IUS expulsion (n=2) was not evaluated. 
Also, another possible limitation is that no interim visit was performed (i.e. 2-3 
months after insertion), which would have provided interesting data on HRQoL 
shortly after LNG-IUS insertion.  
 
The present study concludes that LNG-IUS exerts a positive impact on women’s 
HRQoL and satisfaction, both because it provides its users with additional non-
contraceptive benefits and due to its effectiveness and safety profile as a 
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Table 1. Description of sociodemographic and clinical data. 
Variable Value 
Age (years)  
Mean (SD) 38.7 (5.0) 
< 35 years 20.7% 
35-39 years 37.4% 
40-44 years 27.3% 
45-49 years 14.6% 
Level of education  
Illiterate 1.5% 
Primary education 10.6% 
Secondary education 25.1% 
University education 62.8% 
Employment status  

































9. Figures  
 
Figure 1. Changes in HRQoL between baseline and final visit (scores from SEC-
QoL) and statistical significance (p) between changes in SEC-QoL scores and 
symptoms.  
 
SEC-QoL score at baseline 50.4 47.4 48.6 44.3 37.4 46.3
SEC-QoL score 12 months afterwards 75.1 77.0 71.2 70.2 65.2 72.2
Bleeding intensity (p value) 0.292 0.704 0.523 0.789 0.837 0.714
Painful menstrual periods (p value) <0.001 <0.001 0.004 <0.001 0.007 <0.001
*p <0.001
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